A $21.6 million net income turned into a $29.6 million net loss at Organogenesis.
Organogenesis Holdings Inc. (ORGO) reported a net loss of $29.6 million for Q3 2026, a decline from a net income of $21.6 million in Q3 2025. Revenue fell 70% to $45.5 million, with Advanced Wound Care products down 73% and Surgical & Sports Medicine products down 19%. The company expects full-year revenue to decline 65-68% from 2025. Management will discuss results in a conference call.
How this was made
The 30-second read
Why it matters
The earnings miss and lowered FY guidance are likely to trigger a sell‑off in the stock and may pressure related wound‑care stocks.
Market read
First‑report earnings data for a small‑cap biotech; material for traders watching the sector.
What to watch
Cash balance remains above $20M and the company retains a strong product pipeline that could drive a turnaround later in the year.
Background
Organogenesis Holdings Inc. reported its Q3 2026 results, showing a sharp revenue decline and a swing to a $29.6M net loss.
Ticker impact
Q3 2026 net loss of $29.6M and 70% YoY revenue decline; FY2026 revenue guidance cut to $179.4M‑$200M.
downward pressure as investors price in weaker revenue and loss
The surprise loss and steep revenue decline are material for a small‑cap biotech; no offsetting positive news.
Market effects
Highlights weakness in the advanced wound‑care market and may affect peers in regenerative medicine.
US biotech sector could see modest pullback on the day of the release.
Regenerative‑medicine investors worldwide may reassess exposure to similar small‑cap players.
Counterpoint
If the loss reflects a temporary market reset, the stock could be oversold and present a buying opportunity.
Key entities
- companyOrganogenesis Holdings Inc.
Regenerative‑medicine firm listed on Nasdaq (ORGO).
